AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 202 min read$MPLT

Kreitzer Anatol sold $1.3M of MPLT

Kreitzer Anatol (Chief Discovery Officer) sold 36,284 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $37.09 ($36.13–$38.39, $1.35M total) across 7 trades over 2026-07-15 to 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kreitzer Anatol
Published Jul 20, 2026, 10:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 20, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity: Kreitzer Anatol, Chief Discovery Officer, sold shares in multiple trades at $36.13 to $38.39 per share, totaling about $1.35M, under a 10b5-1 plan.

02

Market read

Primarily a sentiment/positioning datapoint; no new business or financial guidance is provided.

03

What to watch

Traders may over-weight insider sales; without concurrent news on pipeline, trials, or financing, the signal is likely weak.

Relevance 5/10Novelty 5/10Timing: filed on 2026-07-20, covering sales executed 2026-07-15 to 2026-07-17

Background

The article is an SEC Form 4 insider transaction for MapLight Therapeutics, Inc. (MPLT).

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

MapLight Therapeutics insider Form 4 shows CDO Kreitzer Anatol sold 36,284 shares in open-market trades for about $1.35M under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment and positioning rather than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no accompanying operational or guidance change.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • issuer
    MapLight Therapeutics, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Kreitzer Anatol

    Chief Discovery Officer who executed open-market sales under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 29
$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

rttnews.com7 min
JUL 28
Med

MapLight Therapeutics stock crashes on Phase II schizophrenia data

MapLight Therapeutics shares fell 71.9% after it reported mixed Phase II schizophrenia trial data, dropping from $35.23 (July 23 close) to $9.90 (July 27 close). The Nasdaq-listed company raised $250m in an Oct 2025 IPO for its ZEPHYR trial. MapLight aims to compete with BMS’s Cobenfy, which GlobalData projects could reach $2.2bn in 2031.

yahoo.com4 min
JUL 27
$MPLTMed

MapLight Reports Mixed Results From Phase 2 ZEPHYR Schizophrenia Trial; Shares Fall

MapLight Therapeutics (MPLT) reported mixed topline Phase 2 ZEPHYR schizophrenia results. The 210/3 mg twice-daily dose met the primary PANSS improvement endpoint (effect size 0.37 mITT, p=0.002; 0.50 completers, p=0.002). The 330/6 mg once-daily arm was not statistically significant. Company said cognition improved in impaired patients (effect size 0.51, p=0.041). Shares fell.

rttnews.com4 min
JUL 27
$MPLTHighAI 8/10

MapLight Therapeutics stock tumbles 40% on trial results By Investing.com

MapLight Therapeutics (NASDAQ:MPLT) shares fell about 40% after topline Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia. The 210/3 mg twice-daily dose met the primary PANSS endpoint at Week 5 versus placebo, while the 330/6 mg once-daily dose did not. The twice-daily arm also showed significant secondary endpoints; safety was generally tolerable. The company plans an FDA End-of-Phase 2 meeting.

investing.com3 min
JUN 22
$MPLTMed

MapLight's ML-004 Misses Phase 2 Endpoint But Shows Irritability Signal In Adolescents

MapLight Therapeutics reported topline Phase 2 IRIS results for ML-004 in autism. The study of 161 patients did not meet its primary endpoint: caregiver-reported ABI Social Communication Domain change at week 12 vs placebo. In a prespecified adolescent (12–17) subgroup with baseline irritability, ML-004 improved ABC-I irritability (effect size 1.33, nominal p=0.013) and CGI-I (effect size 1.08, nominal p=0.036). The drug was well tolerated. The company plans an FDA End-of-Phase 2 meeting.

rttnews.com4 min